Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy
Introduction
Diabetic nephropathy is the most common cause of chronic renal failure requiring renal-replacement therapy. Diabetic nephropathy is characterized by endothelial injuries resulting in the so-called exudative lesions in the glomeruli (Fioretto and Mauer, 2007). In addition to such microvascular damages, diabetes mellitus is also associated with the development of macrovascular injuries; the combination of both micro- and macrovascular complications explains early mortality (Tuomilehto et al., 1998). Evidence of widespread endothelial dysfunction has been found in patients with diabetes (Hink et al., 2001).
The importance of sphingosine 1-phosphate (Sph-1-P) as an intercellular lipid mediator has been established (Yatomi et al., 2000; Yatomi, 2006). Sph-1-P is synthesized by the sphingosine kinase-catalyzed phosphorylation of sphingosine. Blood platelets store Sph-1-P abundantly, although erythrocytes have recently attracted attention as another source of blood Sph-1-P (Pappu et al., 2007). Vascular endothelial cells and smooth muscle cells (SMCs) respond dramatically to this bioactive lipid mainly through the family of G protein-coupled Sph-1-P receptors named S1P1, 2, 3, 4, and 5, which were originally referred to as endothelial differentiation gene (EDG)-1, -5, -3, -6, and -8, respectively. The site of expression and the manner of signal transduction vary among the different isoforms of these Sph-1-P receptors. S1P1 and S1P2 are the two most important S1P receptors expressed in vascular cells (Inoki et al., 2006; Sanchez et al., 2007), with contrasting characteristics. S1P1 is mainly expressed in endothelial cells and participates in maintaining vascular homeostasis through assembly of adherens junctions (Lee et al., 1999), enhancement of survival potency (Hisano et al., 1999), promotion of barrier integrity (Garcia et al., 2001; Singleton et al., 2006), successful maturation (Liu et al., 2000), NO production (Kwon et al., 2001; Levine et al., 2007), cooperation with activated protein C (Feistritzer and Riewald, 2005; Finigan et al., 2005), and other studied mechanisms (Armulik et al., 2005). On the other hand, adult smooth muscle cells express S1P2, rather than S1P1 (Kluk and Hla, 2001). In addition, S1P2 seems to have adverse effects against vascular homeostasis because the signal through S1P2 results in suppression of eNOS (Skoura et al., 2007), SMC contraction (Ohmori et al., 2003), or the inhibition of SMC migration (Ryu et al., 2002). Therefore, S1P2 has an essential role in pathological angiogenesis (Skoura et al., 2007). In this manner, the responses to Sph-1-P differ between S1P1 and S1P2 (Donati et al., 2005; Okamoto et al., 2000; Sugimoto et al., 2003).
Furthermore, in in vitro models, Sph-1-P was reported to stimulate mesangial proliferation (Hanafusa et al., 2002), which should be associated with signal transduction through S1P2 and S1P3 (Katsuma et al., 2005). We previously reported the involvement of Sph-1-P in the contraction of mesangial cells through the activity of S1P2 (Osada et al., 2007). In addition, it was recently reported that the balance of S1P1 and S1P2 determined the regulation of vascular permeability (Sanchez et al., 2007). These previous data suggest that Sph-1-P signals through S1P1 and S1P2 play important roles in the etiopathogenesis of glomerular changes, especially in diabetic nephropathy. However, expression patterns of S1P1 and S1P2 in diabetic nephropathy remain uncertain. Here, we revealed that balance of vasculoprotective S1P1 and antagonistic S1P2 was disturbed in the glomeruli of a rat model of diabetic nephropathy, suggesting that such expression patterns may be involved in the dysfunction of glomerular endothelial cells.
Section snippets
Animals
Food was withheld for 24 h from 8-week-old female Sprague-Dawley rats, and the rats were divided into two groups. The diabetic group (n=8) was intravenously injected with streptozotocin (Sigma Chemical, St. Louis, MO) freshly dissolved in a 0.02-M citrate buffer at pH 4.5 and delivered at a dose of 40 mg/kg body weight. The non-diabetic control group (n=6) was injected with the 0.02-M citrate buffer. Rats were fed ad libitum with a standard chow and were kept under a 12-h light–dark cycle. All
Exudative lesions in the glomeruli of diabetic rats
The laboratory data at the sacrifice are summarized in Table 1. The serum creatinine levels were the same in the two groups. In light-microscopic analysis with PAS and PAM staining, the control rats did not exhibit any pathological abnormalities in their kidneys (Fig. 1A and B). In diabetic rats, no sclerotic lesion was observed in PAS (data not shown) and PAM staining. However, morphometric analysis revealed that mesangial matrix area (PAM-positive area in the glomerulus) in diabetic rats was
Discussion
In diabetic nephropathy, one of the typical pathological changes is endothelial injury consisting of the so-called exudative lesions. In this type of lesion, eosinophilic homogenous material accumulates between the endothelial cells and the glomerular basement membrane of the capillary loops, possibly as a result of changes in endothelial permeability (Fioretto and Mauer, 2007). In our study, diabetic rats with high glucose levels were obtained by the intraperitoneal injection of streptozotocin
Acknowledgement
This work was supported by a policy-based medical service network for kidney diseases in Japan.
References (29)
- et al.
Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation
Blood
(2005) - et al.
Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation
J Biol Chem
(2005) - et al.
Histopathology of diabetic nephropathy
Semin Nephrol
(2007) - et al.
Induction and suppression of endothelial cell apoptosis by sphingolipids: a possible in vitro model for cell–cell interactions between platelets and endothelial cells
Blood
(1999) - et al.
Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor
Biochem Biophys Res Commun
(2006) - et al.
Transcriptional regulation of connective tissue growth factor by sphingosine 1-phosphate in rat cultured mesangial cells
FEBS Lett
(2005) - et al.
Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production
J Biol Chem
(2001) - et al.
Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate
Cell
(1999) - et al.
Agonist-modulated regulation of AMP-activated protein kinase in endothelial cells: Evidence for a AMPKuRac1uAktueNOS pathway
J Biol Chem
(2007) - et al.
Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family
J Biol Chem
(2006)
Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells
Blood
Endothelial/pericyte interactions
Circ Res
Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P2 receptor
FASEB J
Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement
J Clin Invest
Cited by (31)
Resveratrol inhibits high glucose-induced activation of AP-1 and NF-κB via SphK1/S1P2 pathway to attenuate mesangial cells proliferation and inflammation
2019, Journal of Functional FoodsCitation Excerpt :The SphK1 transfection assay further showed that RSV significantly inhibited the SphK1 activity in MCs transfected with SphKWT under normal glucose condition, confirming that RSV exerted a relative specific effect on SphK1 independent on its hyperglycemic effect. Of these S1P receptors, S1P2 receptor was mainly expressed in MCs and played an essential role in pathological angiogenesis, leading to DN (Imasawa et al., 2010). S1P2 receptor mediated S1P-induced FN upregulation and MCs proliferation by activating MAPK signaling pathway under HG conditions (Liu et al., 2012).
S1P2 receptor mediates sphingosine-1-phosphate-induced fibronectin expression via MAPK signaling pathway in mesangial cells under high glucose condition
2012, Experimental Cell ResearchCitation Excerpt :Kawanabe et al. showed that the combination S1P and S1P2 antagonist JTE-013 injection promoted wound healing in diabetic mice, indicating that specific regulation of S1P modulated responses including granulation tissue formation and angiogenesis might be achieved by S1P2 antagonists [37,38]. Imasawa et al. believed that the balance of S1P2 and S1P1 receptor expression determined the regulation of vascular permeability in glomeruli, and S1P2 receptor was mainly expressed by mesangial cells and played an essential role in pathological angiogenesis leading to diabetic nephropathy [39]. However, which subtype of S1P receptors mediate S1P-induced fibronectin expression in mesangial cells resulting in extracellular matrix accumulation and eventually leading to renal fibrosis in diabetes is still unknown.
Synthesis and characterization of [<sup>125</sup>I]TZ6544, a promising radioligand for investigating sphingosine-1-phosphate receptor 2
2020, Nuclear Medicine and BiologyCitation Excerpt :S1PR2 couples with Gi, Gq, and G12/13 group of G proteins, which modulate various cellular signaling pathways including cell growth and survival, migration, and adhesion in inflammation, fibrosis, and cancer [3]. Diabetic nephropathy (DN) is characterized by the progressive damage and death of glomerular podocytes, resulting in exudative lesions in glomeruli, renal sclerosis, and renal fibrosis [4–6]. Recent data indicate that activation of sphingosine-kinase-1/S1P/S1PR2 signaling pathway contributes to the development of DN [7–11].
Synthesis and evaluation of highly selective quinazoline-2,4-dione ligands for sphingosine-1-phosphate receptor 2
2022, RSC Medicinal ChemistryThe apoM/S1P Complex—A Mediator in Kidney Biology and Disease?
2021, Frontiers in Medicine